肾衰竭风险方程与慢性肾脏病患者医疗费用
该回顾性队列研究纳入加拿大萨斯喀彻温省多学科CKD门诊的1003例eGFR 15-59 ml/min per 1.73 m2成人患者,按eGFR和肾衰竭风险方程分层,比较5年内住院、就诊和处方药费用。结果显示高风险患者上述费用更高,在eGFR 15-29 ml/min per 1.73 m2组中差异更明显。
要点
- 在eGFR 15-29 ml/min per 1.73 m2组,高风险患者住院费用、就诊费用和药物费用均高于低风险患者。
- 在eGFR 30-59 ml/min per 1.73 m2组,高风险患者仅药物费用显著高于低风险患者,住院和就诊费用差异未达统计学显著。
- 高风险且eGFR 15-29 ml/min per 1.73 m2的患者与住院费用、就诊和药物利用的关联更强。
核心结论
- 在多学科门诊随访的eGFR 15-59 ml/min per 1.73 m2的CKD患者中,经肾衰竭风险方程评估为高风险的患者住院、就诊和药物费用高于低风险患者。
- eGFR 15-29 ml/min per 1.73 m2的高风险CKD患者与住院费用、就诊和药物利用的关联更强。
研究设计与样本
- 回顾性队列研究,纳入加拿大萨斯喀彻温省多学科CKD门诊的成人CKD患者,eGFR为15-59 ml/min per 1.73 m2,共1003例。
- 数据收集时间为2004年1月1日至2012年12月31日,随访5年至2017年12月31日。
- 按eGFR和肾衰竭风险方程评估的进展风险分层,比较住院、医生就诊和处方药的数量与费用。
主要发现
- 在eGFR 15-29 ml/min per 1.73 m2组,高风险患者与低风险患者5年住院费用分别为89,265加元与48,374加元(P=0.008)。
- 在eGFR 15-29 ml/min per 1.73 m2组,高风险患者与低风险患者医生就诊费用分别为23,423加元与11,231加元(P<0.001),药物费用分别为21,853加元与16,757加元(P=0.01)。
- 在eGFR 30-59 ml/min per 1.73 m2组,高风险患者与低风险患者住院费用分别为55,944加元与36,740加元(P=0.10),医生就诊费用分别为13,414加元与10,370加元(P=0.08),差异未达统计学显著。
- 在eGFR 30-59 ml/min per 1.73 m2组,高风险患者与低风险患者药物费用分别为20,394加元与14,902加元(P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with CKD exhibit heterogeneity in their rates of progression to kidney failure. The kidney failure risk equation (KFRE) has been shown to accurately estimate progression to kidney failure in adults with CKD. Our objective was to determine health care utilization patterns of patients on the basis of their risk of progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study of adults with CKD and eGFR of 15-59 ml/min per 1.73 m2 enrolled in multidisciplinary CKD clinics in the province of Saskatchewan, Canada. Data were collected from January 1, 2004 to December 31, 2012 and followed for 5 years (December 31, 2017). We stratified patients by eGFR and risk of progression and compared the number and cost of hospital admissions, physician visits, and prescription drugs. RESULTS: In total, 1003 adults were included in the study. Within the eGFR of 15-29 ml/min per 1.73 m2 group, the costs of hospital admissions, physician visits, and drug dispensations over the 5-year study period comparing high-risk patients with low-risk patients were (Canadian dollars) $89,265 versus $48,374 (P=0.008), $23,423 versus $11,231 (P<0.001), and $21,853 versus $16,757 (P=0.01), respectively. Within the eGFR of 30-59 ml/min per 1.73 m2 group, the costs of hospital admissions, physician visits, and prescription drugs were $55,944 versus $36,740 (P=0.10), $13,414 versus $10,370 (P=0.08), and $20,394 versus $14,902 (P=0.02) in high-risk patients in comparison with low-risk patients, respectively, for progression to kidney failure. CONCLUSIONS: In patients with CKD and eGFR of 15-59 ml/min per 1.73 m2 followed in multidisciplinary clinics, the costs of hospital admissions, physician visits, and drugs were higher for patients at higher risk of progression to kidney failure by the KFRE compared with patients in the low-risk category. The high-risk group of patients with CKD and eGFR of 15-29 ml/min per 1.73 m2 had stronger association with hospitalizations costs, physician visits, and drug utilizations.
引用
- Prasad B, Osman M, Jafari M, et al. Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease. Clin J Am Soc Nephrol. 2021. PMID: 34969699. doi:10.2215/CJN.06770521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。